Total Payments
$1.1M
2024 Payments
$373,315
Companies
1
Transactions
27
Medicare Patients
461
Medicare Billing
$22,414
Payment Breakdown by Category
Research$1.1M (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 27 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $1.1M | 27 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $373,315 | 6 | Eli Lilly and Company ($373,315) |
| 2023 | $390,079 | 6 | Eli Lilly and Company ($390,079) |
| 2022 | $153,625 | 5 | Eli Lilly and Company ($153,625) |
| 2021 | $137,820 | 3 | Eli Lilly and Company ($137,820) |
| 2020 | $17,090 | 2 | Eli Lilly and Company ($17,090) |
| 2019 | $39,900 | 1 | Eli Lilly and Company ($39,900) |
| 2018 | $11,075 | 4 | Eli Lilly and Company ($11,075) |
All Payment Transactions
27 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $100.00 | Research |
| Study: A SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3954068 IN PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 01/04/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $144,673.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 01/04/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $130,325.00 | Research |
| Study: A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | ||||||
| 01/04/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $41,197.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 01/04/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $32,515.00 | Research |
| Study: GLOBAL STUDY TO INVESTIGATE SAFETY AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 01/04/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $24,505.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 05/08/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $72,175.00 | Research |
| Study: A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | ||||||
| 01/05/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $121,675.00 | Research |
| Study: ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 01/05/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $100,300.00 | Research |
| Study: A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | ||||||
| 01/05/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $81,709.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 01/05/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $12,600.00 | Research |
| Study: GLOBAL STUDY TO INVESTIGATE SAFETY AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 01/05/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,620.00 | Research |
| Study: DONANEMAB FOLLOW-ON STUDY: SAFETY TOLERABILITY AND EFFICACY IN SYMPTOMATIC ALZHEIMER'S DISEASE WITH VALIDATION OF REMOTE NEUROPSYCHOLOGICAL ASSESSMENTS | ||||||
| 10/06/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $12,125.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 02/03/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $14,400.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 01/05/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $123,530.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 01/05/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,970.00 | Research |
| Study: DONANEMAB FOLLOW-ON STUDY: SAFETY, TOLERABILITY, AND EFFICACY IN SYMPTOMATIC ALZHEIMER'S DISEASE WITH VALIDATION OF REMOTE NEUROPSYCHOLOGICAL ASSESSMENTS | ||||||
| 01/05/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: A PHASE 3, OPEN-LABEL, PARALLEL-GROUP, 2-ARM STUDY TO INVESTIGATE AMYLOID PLAQUE CLEARANCE WITH DONANEMAB COMPARED WITH ADUCANUMAB-AVWA IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 06/16/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,470.00 | Research |
| Study: DONANEMAB FOLLOW-ON STUDY: SAFETY, TOLERABILITY, AND EFFICACY IN SYMPTOMATIC ALZHEIMER'S DISEASE WITH VALIDATION OF REMOTE NEUROPSYCHOLOGICAL ASSESSMENTS | ||||||
| 01/13/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $134,650.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 01/13/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,700.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 09/09/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,290.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 01/08/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $14,800.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 01/10/2019 | Eli Lilly and Company | — | — | Cash or cash equivalent | $39,900.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 08/24/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,200.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | ||||||
| 08/24/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,875.00 | Research |
| Study: A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $284,975 | 4 |
| A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | Eli Lilly and Company | $202,500 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $156,798 | 2 |
| ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $121,675 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $100,300 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $81,709 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $62,800 | 4 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $55,597 | 2 |
| GLOBAL STUDY TO INVESTIGATE SAFETY AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $45,115 | 2 |
| DONANEMAB FOLLOW-ON STUDY: SAFETY, TOLERABILITY, AND EFFICACY IN SYMPTOMATIC ALZHEIMER'S DISEASE WITH VALIDATION OF REMOTE NEUROPSYCHOLOGICAL ASSESSMENTS | Eli Lilly and Company | $4,440 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $2,200 | 1 |
| A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY | Eli Lilly and Company | $1,875 | 1 |
| DONANEMAB FOLLOW-ON STUDY: SAFETY TOLERABILITY AND EFFICACY IN SYMPTOMATIC ALZHEIMER'S DISEASE WITH VALIDATION OF REMOTE NEUROPSYCHOLOGICAL ASSESSMENTS | Eli Lilly and Company | $1,620 | 1 |
| A PHASE 3, OPEN-LABEL, PARALLEL-GROUP, 2-ARM STUDY TO INVESTIGATE AMYLOID PLAQUE CLEARANCE WITH DONANEMAB COMPARED WITH ADUCANUMAB-AVWA IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $600.00 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY | Eli Lilly and Company | $600.00 | 1 |
| A SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3954068 IN PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $100.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 103 | 106 | $123,051 | $4,773 |
| 2022 | 3 | 118 | 120 | $132,423 | $5,369 |
| 2021 | 5 | 218 | 228 | $291,523 | $11,467 |
| 2020 | 1 | 22 | 23 | $22,953 | $805.32 |
Total Patients
461
Total Services
477
Medicare Billing
$22,414
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 70450 | Ct scan head or brain without contrast | Facility | 2023 | 63 | 64 | $61,504 | $2,277 | 3.7% |
| 70498 | Ct scan of blood vessels of neck with contrast | Facility | 2023 | 12 | 13 | $26,247 | $929.63 | 3.5% |
| 70496 | Ct scan of blood vessels of head with contrast | Facility | 2023 | 11 | 12 | $23,196 | $891.96 | 3.8% |
| 72125 | Ct scan of upper spine without contrast | Facility | 2023 | 17 | 17 | $12,104 | $674.26 | 5.6% |
| 70450 | Ct scan head or brain without contrast | Facility | 2022 | 81 | 83 | $79,763 | $2,838 | 3.6% |
| 70553 | Mri scan of brain before and after contrast | Facility | 2022 | 18 | 18 | $39,132 | $1,768 | 4.5% |
| 72125 | Ct scan of upper spine without contrast | Facility | 2022 | 19 | 19 | $13,528 | $762.31 | 5.6% |
| 70450 | Ct scan head or brain | Facility | 2021 | 121 | 131 | $125,891 | $4,561 | 3.6% |
| 70553 | Mri scan of brain before and after contrast | Facility | 2021 | 23 | 23 | $50,002 | $2,324 | 4.6% |
| 70496 | Ct scan of blood vessel of head with contrast | Facility | 2021 | 28 | 28 | $54,124 | $1,980 | 3.7% |
| 70498 | Ct scan of neck blood vessels with contrast | Facility | 2021 | 22 | 22 | $44,418 | $1,603 | 3.6% |
| 72125 | Ct scan of upper spine | Facility | 2021 | 24 | 24 | $17,088 | $998.20 | 5.8% |
| 70450 | Ct scan head or brain | Facility | 2020 | 22 | 23 | $22,953 | $805.32 | 3.5% |
About Dr. Camilla Lindan, MD
Dr. Camilla Lindan, MD is a Diagnostic Radiology healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124106752.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Camilla Lindan, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $373,315 received in 2024. These payments were reported across 27 transactions from 1 company. The most common payment nature is "" ($1.1M).
As a Medicare-enrolled provider, Lindan has provided services to 461 Medicare beneficiaries, totaling 477 services with total Medicare billing of $22,414. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location San Francisco, CA
- Active Since 11/01/2006
- Last Updated 05/01/2008
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1124106752
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in San Francisco
Dr. Jerome Barakos, M.d, M.D
Diagnostic Radiology — Payments: $2.2M
Diagnostic Radiology $2.2M
Dr. Derk Purcell, M.d, M.D
Diagnostic Radiology — Payments: $2.0M
Diagnostic Radiology $2.0M
Blaise Baxter, Md, MD
Diagnostic Radiology — Payments: $1.1M
Diagnostic Radiology $1.1M
Hari Trivedi, Md, MD
Diagnostic Radiology — Payments: $107,314
Diagnostic Radiology $107,314
Daniel Cooke, Md, MD
Diagnostic Radiology — Payments: $58,072
Diagnostic Radiology $58,072
Dr. Jeanne Laberge, M.d, M.D
Diagnostic Radiology — Payments: $50,208
Diagnostic Radiology $50,208